K-975 is a first-in-class TEAD inhibitor, directly inhibiting YAP/TAZ-TEAD protein-protein interaction and showing a potent anti-tumor effect in malignant pleural mesothelioma. K-975 was covalently bound to an internal cysteine residue located in the palm

KYN-101 (KYN101) is a potent, selective synthetic antagonist of aryl hydrocarbon receptor (AHR) with IC50 of 22 nM in human HepG2 DRE-luciferase reporter assay and 23 nM in murine Hepa1 Cyp-luc assay.KYN-101 reverses IDO/TDO-mediated tumor progression and improves the efficacy of PD-1 blockade in B16 IDO tumor-bearing mice, as well as CT26 colorectal cancer model expressing endogenous high levels of IDO.

2-(2-bromophenyl)-5-chloro-4H-3,1-benzoxazin-4-one is an human neutrophil elastase inhibitor.

SKI-178 is a potent, specific, non-lipid SphK1 inhibitor with Ki of 1.33 uM, displays no significant activity for SphK2 (IC50>25 uM).

SW-100 (SW100) is a potent, selective, brain penetrable HDAC6 inhibitor with IC50 of 2.3 nM, displays >1,000-fold selectivity over all other class I, II, and IV HDAC isoforms.

S-β-(4-Pyridylethyl)-L-cysteine is a specialized biochemical compound commonly used in research applications.

Adaphostin is a novel activator of Fas-mediated death pathway in Bcr/Abl-positive leukaemia.

M351-110 is a V-domain immunoglobulin suppressor of T-cell activation (VISTA) agonist that enhances immune responses, making it a promising candidate for cancer immunotherapy research.

ML202 represents a selective allosteric modulator of human pyruvate kinase M2 (hPK-M2) that specifically enhances phosphoenolpyruvate (PEP) binding cooperativity without significantly affecting adenosine diphosphate (ADP) binding kinetics.

Phevamine A is a phytotoxic secondary metabolite produced by Pseudomonas syringae. This small molecule compound facilitates bacterial proliferation through its ability to suppress host plant defense mechanisms.

VU-29 (DPAP) is a potent, selective and allosteric potentiator of rat mGlu5 receptor with EC50 of 9 nM, displays >50-fold selectivity over mGlu1 and mGlu2 receptor (EC50=557 nM and 1.51 uM).

Hydrophobic inducer of the degradation of stabilized proteins, degrading HaloTag2 fusion proteins

ARN-21934 is a novel potent and highly selective inhibitor for human topoisomerase II α over β.

AGI-001 is an orally bioavailable, competitive antagonist of 5-HT1A/1B receptors with reversible binding properties. This compound also functions as a partial agonist at β-adrenergic receptors, making it a valuable pharmacological tool for investigating neurological disorders.

ElteN378 is a selective FKBP12e inhibitor with potential therapeutic applications in neurodegenerative disorders and oncology. This compound shows particular relevance for research involving Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), as well as various proliferative disorders and malignancies.

GSK3987 functions as a dual agonist for both LXRα and LXRβ nuclear receptors, demonstrating potent activation with EC50 values of 50 nM (LXRα-SRC1) and 40 nM (LXRβ-SRC1). This compound effectively upregulates key metabolic regulators ABCA1 and SREBP-1c, while simultaneously promoting cholesterol efflux from cells and stimulating intracellular triglyceride deposition.

L82-G17 is a selective, uncompetitive inhibitor that specifically targets DNA ligase I (Lig I). This compound uniquely blocks the final stage of the ligation process by interfering with phosphodiester bond formation. Due to its specific mechanism of action, L82-G17 serves as a valuable molecular probe for studying ligase catalytic activity.

LASV inhibitor 3.3 (LAMP1 inhibitor 3.3) is a specific inhibitor of Lassa fever virus (LASV, IC50=1.8 uM), inhibits LASV GP-mediated infection and cross-links to the LASV receptor, LAMP1, in cells; does not inhibits the GP-mediated infection of LCMV, LuJo

SSAA09E3 is a potent viral entry inhibitor that effectively blocks SARS-CoV infection. In cellular assays, it demonstrates inhibitory activity against SARS/HIV pseudotyped viruses in 293T cells (EC50 = 9.7 μM) and shows even greater potency against authentic SARS-CoV in Vero cells (EC50 = 0.15 μM).

STING-IN-2 (C-170) is a covalent-binding small molecule that potently suppresses STING activity. It demonstrates effective inhibition against both murine (mmSTING) and human (hsSTING) variants, making it a valuable tool for investigating autoinflammatory disorders.

PKZ18 is a novel antibiotic that effectively suppresses bacterial growth, exhibiting MIC values ranging from 32 to 64 μg/mL against a broad spectrum of Gram-positive bacteria. Its mechanism involves the selective inhibition of glycyl-tRNA synthetase mRNA transcription and translation in vivo. PKZ18 specifically targets stem I specifier loops in Gram-positive bacteria, disrupting T-box-mediated transcriptional read-through of downstream genes. By interfering with codon-anticodon recognition, it blocks essential tRNA binding and demonstrates a high barrier to resistance development.

HOIPIN-1 (JTP-0819958, HOIP inhibitor-1) is a chemical inhibitor of linear ubiquitin chain assembly complex (LUBAC, IC50=2.8 uM), specifically generates Met1-linked linear ubiquitin chains through the ubiquitin ligase activity in HOIP, and activates the N

UCF-101 is a selective inhibitor of the pro-apoptotic mitochondrial serine protease Omi/HtrA2 involved in the cellular response to thermal and oxidative stress.

Novel mucolipin 1 (ML1) agonist, inducing lysosomal Ca2+ release, ameliorating muscular dystrophies and activating TFEB to correct lysosomal insufficiency in mdx mice

JR-AB2-011 is a potent and selective inhibitor of mTORC2 kinase activity. It markedly reduces mTORC2 signaling and IC50 while enhancing apoptotic levels in GBM cells.

NSC 370284 is a small molecule that directly binds to and inhibits STAT3/5, significantly and selectively suppresses the viability of AML cells with high level of TET1 expression both in vitro and in vivo.

DB818 (DB-818, DB 818) is a small molecule inhibitor of HOXA9/DNA interaction through binding as minor groove DNA ligand on the HOXA9 cognate sequence.

SR31527 is a novel allosteric Kinesin-like protein KIFC1 inhibitor that inhibits microtubule-stimulated KIFC1 ATPase activity with IC50 of 6.6 uM, binds directly to KIFC1 with Kd of 25.4 nM.

NPD8733 (NPD-8733) is a small-molecule ligand of valosin-containing protein (VCP)/p97, binds to the D1 domain of VCP/p97.

MT 63-78 is a specific and effective direct AMPK activator (EC50: 25 μM). MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects. MT 63–78 also causes cell mitotic arrest and apoptosis.